Learn what zuranolone is, how it works as a fast-acting GABAA-modulating antidepressant, and why it’s a breakthrough for major depressive disorder and postpartum depression, with key clinical trial data on onset, durability, and dosing.
Discover how AI-driven pharmacovigilance uses NLP and machine learning to transform drug safety monitoring—automating case intake, enabling real-time signal detection, and creating dynamic, data-driven risk profiles across EHRs, social media, and global safety databases.
Discover how generative AI is transforming small molecule drug discovery by designing novel compounds in silico, optimizing potency and ADMET profiles, and enabling closed-loop discovery cycles across oncology, fibrosis, infectious disease, and CNS disorders.
Discover how AI-driven pharmacovigilance is shifting drug safety from slow, retrospective reporting to real-time, predictive intelligence. Learn how machine learning, NLP, and multi-source data integration improve adverse event detection, benefit–risk assessment, and patient protection at scale.
Learn how erenumab, a CGRP receptor–blocking monoclonal antibody, is transforming migraine prevention. Discover its mechanism, benefits for episodic and chronic migraine, and why it outperforms many traditional oral preventives.
Discover how orforglipron, a first‑in‑class oral GLP‑1 receptor agonist, delivers injectable‑level weight loss and glycemic control in a once‑daily pill, with phase 2 data in obesity and type 2 diabetes.
Discover how AI and machine learning are revolutionizing pharmacovigilance by scanning social media, wearables, EHRs, and search data to detect hidden drug safety signals in near real time and improve patient safety.
Learn what deucravacitinib is, how this first-in-class selective TYK2 inhibitor works, and why it’s changing the treatment landscape for moderate-to-severe plaque psoriasis and other autoimmune diseases, with data from pivotal phase 3 clinical trials.
Discover how tirzepatide, a dual GIP/GLP‑1 receptor agonist, outperforms traditional GLP‑1 drugs for obesity and type 2 diabetes by enhancing insulin secretion, improving glucose control, and driving bariatric‑surgery‑level weight loss in clinical trials.
Discover how artificial intelligence and machine learning are revolutionizing pharmacovigilance. Learn key AI use cases in drug safety, from automated case intake and smart triage to advanced signal detection and real‑time risk–benefit assessment.